DE69507470D1 - Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren - Google Patents

Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren

Info

Publication number
DE69507470D1
DE69507470D1 DE69507470T DE69507470T DE69507470D1 DE 69507470 D1 DE69507470 D1 DE 69507470D1 DE 69507470 T DE69507470 T DE 69507470T DE 69507470 T DE69507470 T DE 69507470T DE 69507470 D1 DE69507470 D1 DE 69507470D1
Authority
DE
Germany
Prior art keywords
tyrosin
diagnosis
cancer
cells express
crkl protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69507470T
Other languages
English (en)
Inventor
John H Groffen
Nora C Heisterkamp
Hoeve Johanna Ten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHILDREN'S HOSPITAL OF LOS ANGELES LOS ANGELES CALIF US
Childrens Hospital Los Angeles
Original Assignee
CHILDREN'S HOSPITAL OF LOS ANGELES LOS ANGELES CALIF US
Childrens Hospital Los Angeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHILDREN'S HOSPITAL OF LOS ANGELES LOS ANGELES CALIF US, Childrens Hospital Los Angeles filed Critical CHILDREN'S HOSPITAL OF LOS ANGELES LOS ANGELES CALIF US
Application granted granted Critical
Publication of DE69507470D1 publication Critical patent/DE69507470D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69507470T 1994-05-13 1995-05-12 Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren Expired - Lifetime DE69507470D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/242,513 US5667981A (en) 1994-05-13 1994-05-13 Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein
PCT/US1995/005957 WO1995031545A2 (en) 1994-05-13 1995-05-12 Diagnostics and treatments for cancers expressing tyrosine phosphorylated crkl protein

Publications (1)

Publication Number Publication Date
DE69507470D1 true DE69507470D1 (de) 1999-03-04

Family

ID=22915067

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69507470T Expired - Lifetime DE69507470D1 (de) 1994-05-13 1995-05-12 Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren

Country Status (10)

Country Link
US (1) US5667981A (de)
EP (1) EP0759986B1 (de)
JP (1) JPH10503365A (de)
AT (1) ATE175996T1 (de)
AU (1) AU691927B2 (de)
CA (1) CA2190161A1 (de)
DE (1) DE69507470D1 (de)
IL (1) IL113720A0 (de)
WO (1) WO1995031545A2 (de)
ZA (1) ZA953912B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309692B1 (en) 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6686165B2 (en) 1997-05-20 2004-02-03 Erasmus Universiteit Rotterdam Recognition of tumor-specific gene products in cancer
DE69822149T2 (de) 1997-05-20 2005-03-03 Erasmus Universiteit Rotterdam Erkennung von tmorspezifische genprodukte
WO1999067380A1 (en) * 1998-06-22 1999-12-29 Temple University - Of The Commonwealth System Of Higher Education c-Cbl SUPPRESSION OF NEOPLASTIC TRANSFORMATION
US20080280771A1 (en) * 2000-02-08 2008-11-13 Regents Of The University Of Michigan Protein MicroarraySystem
US20050230315A1 (en) * 2003-01-13 2005-10-20 Regents Of The University Of Michigan Protein microarray system
WO2001071663A1 (fr) * 2000-03-23 2001-09-27 Japan Science And Technology Corporation Methode d'extraction de lignee cellulaire
CA3081228C (en) 2001-09-10 2022-02-15 Meso Scale Technologies, Llc Assay buffer, compositions containing the same, and methods of using the same
EP2131198B1 (de) * 2001-09-20 2013-03-27 Board of Regents, The University of Texas System Messung der zirkulierenden therapeutischen Antikörper-, Antigen- und Antigen-/Antikörperkomplexe unter Verwendung enzymgekoppelter Immunadsorptionstests
US20030190688A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology, Inc. Methods for detecting BCR-ABL signaling activity in tissues using phospho-specific antibodies
US20060063156A1 (en) * 2002-12-06 2006-03-23 Willman Cheryl L Outcome prediction and risk classification in childhood leukemia
WO2004060055A1 (ja) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha Wt1遺伝子トランスジェニック動物
WO2005040199A1 (en) * 2003-10-27 2005-05-06 Medvet Science Pty Ltd A bidentate motif and methods of use
WO2006086111A2 (en) * 2005-02-10 2006-08-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
BRPI0915718A2 (pt) * 2008-06-20 2017-06-20 Univ Texas peptídeos de direção crkl
WO2012030738A2 (en) * 2010-08-30 2012-03-08 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
US9637523B2 (en) 2012-08-31 2017-05-02 Westfaelische Wilhelms-Universitaet Muenster Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease
JP7300642B2 (ja) * 2019-06-14 2023-06-30 国立大学法人浜松医科大学 特発性肺線維症の予後予測方法
CN115991789B (zh) * 2022-07-14 2024-06-04 华中科技大学 一种基于sh2超亲体的融合蛋白及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH082799B2 (ja) * 1987-03-06 1996-01-17 秀雄 麦島 骨髄線維症治療剤
WO1993003377A1 (en) * 1991-07-31 1993-02-18 Ziltener Hermann J Method for the detection of phosphotyrosine residues
CA2054602C (en) * 1991-10-31 2003-04-22 Anthony Pawson Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system

Also Published As

Publication number Publication date
EP0759986B1 (de) 1999-01-20
JPH10503365A (ja) 1998-03-31
ATE175996T1 (de) 1999-02-15
AU691927B2 (en) 1998-05-28
IL113720A0 (en) 1995-10-31
US5667981A (en) 1997-09-16
EP0759986A1 (de) 1997-03-05
AU2689095A (en) 1995-12-05
CA2190161A1 (en) 1995-11-23
WO1995031545A3 (en) 1996-08-01
WO1995031545A2 (en) 1995-11-23
ZA953912B (en) 1996-01-16

Similar Documents

Publication Publication Date Title
DE69507470D1 (de) Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
WO1998035693A3 (en) Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease
DE69519796D1 (de) PTPalpha-Bestimmung in der Tumordiagnose und -Prognose
BR9609270A (pt) Polinucleotídeo isolado e purificado peptídeo isolado e purificado processo para detectar a presença da câncer mamário em um paciente e kit para a detecção da presença de células neoplásticas mamárias em uma amostra
DE69841164D1 (de) Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung
DE69737788D1 (de) Reagenzien und methoden zum nachweis von erkrankungen der brust
ATE332979T1 (de) Detektion von änderungen von tumor-suppressor genen zur diagnose von krebs
AU2002246668A1 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
Zhao et al. Expression profile of genes associated with antimetastatic gene: nm23‐Mediated metastasis inhibition in breast carcinoma cells
WO1999058692A3 (en) Human apoptosis associated proteins
ATE350662T1 (de) Markerproteine für prostatakrebs
WO2003021229A3 (en) Diagnostic and prognostic tests
WO2000017355A3 (en) Human cytoskeleton associated proteins
IL151448A0 (en) Proteins
Fang et al. High levels of CD 20 expression predict good prognosis in chronic lymphocytic leukemia
DE69126038D1 (de) Diagnose von krebs-metastasen durch das mts-1 gen
NO982588D0 (no) FremgangsmÕte for diagnose og behandling av plate epizelkarsinom
WO2000005374A3 (en) Molecules associated with cell proliferation
BR0303092A (pt) Portfólio para prognóstico de câncer de mama
WO2000020604A3 (en) Oxidoreductase molecules
ATE363916T1 (de) Die expression von cyclin g1 in tumoren
ATE298003T1 (de) Ein tumorsuppressor namens ts10q23.3
DE69939623D1 (de) Polymorphe marker von prostatakarzinom tumorantigen-1 (pcta-1)
WO2000000609A3 (en) Molecules associated with apoptosis

Legal Events

Date Code Title Description
8332 No legal effect for de